

OVERVIEW

- Global biopharmaceutical company focused on novel therapeutics for unmet medical needs
- 3 core programs reaching clinical phase in 2020 + menopause supplement global commercialisation in Q1 2020
- Targeting US FDA pathways (priority) followed by Europe + NMPA (formerly known as CFDA)
- Core clinical development sites based in North America and Asia

Current progress of pipeline programs → Lead Projects → Other Candidates → Device Candidates → Projected timeline

Note: all projected timelines refer to the estimated commencement time of the indicated stages

Pillar 1 : Acticule (ALS series) – Infectious diseases¹

| Small molecule approach | | IND | | | NDA | | |
|-------------------------|--|------------------------|-------------------|--------------|---------|---|--|
| Program | Indication | Discovery | Lead optimization | IND enabling | Phase I | PhII/III based on LPAD pathway ² | |
| ALS-4 | Anti <i>S. aureus</i> (including MRSA) | → + oral formulation → | | | Q3 2019 | Q1/2 2020 | |
| ALS-2 | Gram+ bacteria | → | | | | | |
| ALS-3 | Gram+ bacteria | → | | | | | |
| ALS-1 | Anti influenza A | → | | Q4 2020 | | | |

Hybrid study
-volunteers + patients
-initial efficacy readout

¹Recent deals in the antibiotic industry (2014-2019): Merck's acquisition of Cubist Pharmaceuticals for US\$ 8.4bn; Roivant's licensing of Intron's Phase II asset for US\$ 657.5m in milestones

²ALS-4's eligibility for the LPAD pathway is subject to the FDA's approval. Targeting other indications in Phase II may affect our valuation. QIDP status can be applied once we identify an indication

Pillar 2 : Claves (CLS series) - Microbiota

| Large molecule approach. Over 70 targets / indications | | IND | | | NDA | |
|--|-----------------|-----------|-------------------|--------------|---------|--------------|
| Program | Indication | Discovery | Lead optimization | IND enabling | Phase I | Phase II/III |
| CLS-1 | Obesity | → | | Q4 2019 | Q2 2020 | Q4 2020 |
| CLS-2 | To be disclosed | → | | | | |
| CLS-3 | To be disclosed | → | | | | |

Pillar 3 : SMART-ACT (SACT series) – Orphan disease drug repurposing platform

| Over 7000 orphan diseases to be screened in the next 5 years | | SMART PHARMA | | IND | | 505b(2) filing ³ | |
|--|-----------------|-------------------------|---------------------|--------------------|--------------------------------------|----------------------------------|--|
| Program | Indication | Computational discovery | In vitro validation | In vivo validation | Preparation of regulatory submission | PhII/III with limited population | |
| | | | (Preclinical) | | | | |
| SACT-1 | Neuroblastoma | → | | | Q4 2019 | Q1 2020 | ready for clinical trial by Q2/Q3 2020 |
| SACT-2 | To be disclosed | → | | | | | |
| SACT-3 | To be disclosed | → | | | | | |

³subject to the FDA's approval

OTHERS

| Program | Modality | Indication | Formulation | Commercialisation |
|--------------------------|------------|---------------------|-------------|-------------------|
| DOI (NLS-2) ⁴ | Supplement | Menopausal symptoms | → | Q1 2020 |

⁴BBC news: "National shortage in hormone replacement therapy adds to the stress of menopause" Aug 2019

| Program | Modality | Indication | Discovery | Lead optimization |
|---------|----------------|-----------------------------------|-----------|-------------------|
| NLS-1 | Small molecule | Endometriosis | → | |
| VLS-2 | Small molecule | Alzheimer's & Parkinson's disease | → | |
| SPLS-1 | Small molecule | Liver cancer | → | |

| Program | Modality | Indication | Lab-based phantom trial | Animal trial |
|---------|--|------------------------|-------------------------|--------------|
| SLS-1 | Robotic catheter platform for intra-operative MRI-guided cardiac catheterization | Heart rhythm disorders | → | |